ESTEVE Reports a 5% Increase in Net Revenue and Strengthens Specialized Company Strategy

ESTEVE Reports Significant Growth in 2024

In its latest annual report, ESTEVE has announced that it has reached net revenues of €744 million for the fiscal year 2024, marking a 5% increase from the previous year. This growth aligns with the company's ongoing strategy to enhance its international presence while focusing on specialized healthcare solutions that genuinely improve the lives of patients.

The increase in revenue can be significantly attributed to the company's pharmaceutical segment, which saw net income grow by over 15%. Notably, ESTEVE derives 75% of its total revenues from international markets, indicating a well-executed global strategy that has amplified its reach beyond Spain, where sales constitute 25% of total earnings. The other 53% originates from various European Union countries, highlighting the company's solid performance in key expanding markets.

In July 2024, ESTEVE expanded its portfolio through the acquisition of HRA Pharma Rare Diseases, which introduces three critical treatments for rare diseases, including Cushing's syndrome and adrenocortical carcinoma. This acquisition exemplifies ESTEVE's commitment to addressing unmet medical needs and solidifying its foothold in both European and US markets.

As the company moves into 2025, ESTEVE continues to focus on specialized therapies. It recently announced plans to acquire an adjuvant treatment considered the standard of care for resectable, high-grade osteosarcoma. Additionally, ESTEVE has completed the licensing process for a biological product targeting children aged 2 to 18 who suffer from severe primary insulin-like growth factor-1 deficiency. These advancements signify ESTEVE's dedication to improving quality of life through innovative solutions.

CEO Staffan Schüberg emphasized that the 2024 results not only validate the company's growth trajectory over the past four years but also reinforce its ongoing commitment to offering highly specialized healthcare solutions. Schüberg is optimistic about the prospects for ESTEVE, asserting that 2025 will be pivotal for the firm as it positions itself as a leading international player in specialized medicine.

Innovation remains a key pillar of ESTEVE's strategy, with €46 million invested in product development and process advancement in 2024, which amounts to more than 6% of its global net revenue. The company is also enhancing its industrial capabilities worldwide, marked by the commencement of a new production facility. This will replace the current plant located in China and will expand the active pharmaceutical ingredients production facility in Celrà, Spain.

In terms of social impact, ESTEVE's treatments reached 8 million patients in 2024, significantly contributing to the quality of life for individuals dealing with health issues across endocrinology, oncology, and pain management amongst other fields. Moreover, the company's substantial investment in sustainability initiatives exceeded €1.3 million, further emphasizing its commitment to diversity and inclusion, as evidenced by a 6.6% increase in staffing with a notable achievement in gender parity, boasting 50% women in management positions.

Towards its goal of achieving net-zero carbon emissions by 2050, ESTEVE made strides in reducing its carbon footprint by 5.8% compared to 2023 and by 10.41% since 2022. The company also reported a 12% reduction in water consumption, showcasing its commitment to environmental sustainability.

Founded in 1929 and headquartered in Barcelona, ESTEVE stands as a global pharmaceutical entity dedicated to enhancing human health through innovative and specialized therapeutic solutions. Its comprehensive portfolio includes not only pharmaceutical products but also development and manufacturing services for third parties. With a strong international presence and adherence to core values of prioritizing people, transparency, and responsibility, ESTEVE continues to make meaningful advancements in the healthcare sector.